Phase 2 trial of the topoisomerase II inhibitor, amrubicin, as second-line therapy in patients with metastatic urothelial carcinoma

Matthew D. Galsky,Noah M. Hahn,Bryan Wong,Karen M. Lee,Pamela Argiriadi,Costantine Albany,Kiev Gimpel-Tetra,Nancy Lowe,Mohamed Shahin,Vaibhav G. Patel,Che-Kai Tsao,William Oh

Phase 2 trial of the topoisomerase II inhibitor, amrubicin, as second-line therapy in patients with metastatic urothelial carcinoma

2015

Matthew D. Galsky
Noah M. Hahn
Bryan Wong
Karen M. Lee
Pamela Argiriadi
Costantine Albany
Kiev Gimpel-Tetra
Nancy Lowe
Mohamed Shahin
Vaibhav G. Patel
Che-Kai Tsao
William Oh

Purpose The purpose of this investigator-initiated multicenter phase II study was to determine the activity of the third-generation synthetic anthracycline, amrubicin, administered as second-line therapy in patients with advanced urothelial carcinoma.

Keywords:

Carcinoma
Metastatic Urothelial Carcinoma
Amrubicin
Topoisomerase-II Inhibitor
Phases of clinical research
Oncology
Bladder cancer
Anthracycline
Internal medicine
Chemotherapy
Medicine
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations